Patient appears profoundly cyanotic with relatively modest functional impairment
Irreversibility
No enzymatic reduction pathway exists
Methemoglobin reductase is inactive against SulfHb
Methylene blue and ascorbic acid — ineffective
Resolution only by RBC senescence
Normal RBC lifespan approximately 120 days
Cyanosis resolves over weeks to months as affected cells cleared
Spectral absorption
SulfHb absorbs light at approximately 620 nm
Same wavelength as MetHb — causes co-oximeter misclassification
Pseudomethemoglobinemia on standard 4-wavelength co-oximetry
Cyanide addition eliminates MetHb peak but not SulfHb peak — diagnostic
Therapeutic Considerations
Evidence base and treatment philosophy
No pharmacologic antidote exists
Unlike methemoglobinemia, no reducing agent reverses SulfHb
Drug cessation and supportive care are the cornerstones of treatment
Expectant management for mild disease
Spontaneous resolution over 120 days as RBCs turn over
Patient education reduces anxiety about persistent cyanosis
Transfusion decision-making
Simple transfusion for symptomatic anemia
Effective at increasing functional hemoglobin mass
Dilutes SulfHb fraction
Exchange transfusion reserved for severe or life-threatening cases
Rapidly normalizes SulfHb fraction
Risk of citrate toxicity and transfusion reactions
Institutional expertise required
Prevention strategy
Medication review in recurrent UTI patients before prescribing phenazopyridine
Limit duration to 2 days maximum for symptom relief
Ensure renal function adequate for drug clearance
Occupational H2S exposure mitigation
Personal protective equipment in high-risk workplaces
Atmospheric monitoring for H2S levels
Bowel regimen for chronic constipation
Prevents endogenous H2S accumulation
Daily laxative in constipated patients on oxidizing drugs
Patient Discharge Instructions
copy discharge instructions
Sulfhemoglobinemia home care instructions
Your blue or grey skin color is caused by a change in your blood from a medication or chemical
The medication has been stopped
Your color will slowly return to normal over several weeks to months as your body makes new blood cells
You do not need to take any special medication at home to reverse this
No antidote or reversal agent exists
The process reverses on its own
Medications to permanently avoid
You must never take the following medications again
Phenazopyridine (Pyridium, AZO) — urinary pain reliever available over the counter
Any medication identified as the cause of your episode
Tell all your doctors and pharmacists about this reaction
It should be listed in your medical records as a drug reaction
Activity and diet at home
Rest as needed if you feel short of breath or tired
Limit strenuous activity until color improves and symptoms resolve
Drink plenty of fluids and eat high-fiber foods
Prevent constipation to reduce sulfur buildup in the gut
No special diet required beyond normal healthy eating
Warning signs — return to the emergency department immediately
Sudden difficulty breathing at rest
Unable to speak full sentences
Fainting or loss of consciousness
Chest pain
Confusion or unusual sleepiness
Worsening color (more blue or grey than at discharge)
Rapid heart rate or palpitations at rest
Feeling very weak or unable to stand
Follow-up plan
See your doctor or hematologist within 1-2 weeks
Blood test to monitor your blood count
Confirm diagnosis with specialized blood test if not yet done
Report any new urinary symptoms or infection to your doctor promptly
Early treatment of UTI prevents recurrence of this condition if that was the cause
References
Guidelines and key sources
Landmark case series and reviews
Lu HC, Shih RD, Marcus S, Ruck B, Jennis T. Pseudomethemoglobinemia: A Case Report and Review of Sulfhemoglobinemia. Archives of Pediatrics and Adolescent Medicine. 1998
Morales A, Walsh R, Brown W, Checinski P, Williams SR. Case Report: Phenazopyridine-Induced Sulfhemoglobinemia in an 83-Year-Old Presenting With Dyspnea. Journal of Emergency Medicine. 2021
Typical geriatric presentation with OTC phenazopyridine
Gopalachar AS, Bowie VL, Bharadwaj P. Phenazopyridine-Induced Sulfhemoglobinemia. Annals of Pharmacotherapy. 2005
Drug mechanism and clinical course
Specialized diagnostic references
Stepanenko T, Zajac G, Czajkowski A, et al. Sulfhemoglobin Under the Spotlight. Biochimica et Biophysica Acta. 2023
Murphy K, Ryan C, Dempsey EM, et al. Neonatal Sulfhemoglobinemia and Hemolytic Anemia Associated With Intestinal Morganella Morganii. Pediatrics. 2015
Neonatal case with exchange transfusion
Campagna G, Espaillat A, Pfeiffer T, et al. Sulfhemoglobinemia Secondary to a Urinary Tract Infection. Journal of Pediatric Hematology/Oncology. 2020
Pediatric UTI-associated case
Langford JS, Sheikh S. Sulfhemoglobinemia Associated With High-Dose Metoclopramide and N-Acetylcysteine. Annals of Emergency Medicine. 1999
Adolescent case with combined drug exposure
ICD-10 and coding
Diagnostic coding references
ICD-10 D74.8 — other methemoglobinemias (used for acquired sulfhemoglobinemia in many coding systems)
No distinct ICD-10 code exists for sulfhemoglobinemia in ICD-10-CM
SNOMED CT concept: sulfhemoglobinemia disorder
ICD-10 T39.1 — poisoning by phenazopyridine if drug-induced context
T65.89 — toxic effects of other specified substances for chemical H2S exposure
Iolascon A, et al. Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology. 2021
Comparative guidance for dyshemoglobinemia diagnosis and management
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.